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The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A,
leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We
show that in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and
associates with massive epigenetic alterations on the DNA methylation, chromatin acces-
sibility and histone modification level, that can be partially recapitulated in an orthogonal cell
line system by the introduction of H3.3-G34W. These epigenetic alterations affect mainly
heterochromatic and bivalent regions and provide possible explanations for the genomic
instability, as well as the osteolytic phenotype of GCTB. The mutation occurs in differentiating
mesenchymal stem cells and associates with an impaired osteogenic differentiation. We
propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3
WT and H3.3 MUT stromal cells and add to H3.3-G34W-associated changes.
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The discovery of mutated histone genes in aggressive cancersraised a lot of interest in the cancer research community dueto their ability to globally alter the epigenomic landscape1. A
frequently mutated histone is the non-canonical histone variant
H3.32,3. In contrast to canonical H3.1 and H3.2, the incorporation
of histone variant H3.3 is replication-independent and its turnover
occurs throughout the cell cycle4. Deposition occurs either via the
histone regulator A (HIRA) chaperone complex at sites of gene
activation or through alpha-thalassemia/mental retardation X-
linked-death domain associated protein (ATRX-DAXX) into het-
erochromatic regions5 and the silent allele of imprinted genes6.
Mouse embryonic stem cells require H3.3 for correct establishment
of H3K27me3 patterns at bivalent promoters of developmentally
regulated genes7,8. While two human genes, H3 histone family
member 3A (H3F3A) and 3B (H3F3B), encode for an identical H3.3
protein, oncogenic mutations occur gene-specifically in different
tumor types. Lysine-27-to-methionine (H3.3-K27M) and glycine-
to-arginine or valine substitution (H3.3-G34R/V) in pediatric
gliomas9, as well as glycine-34-to-tryptophan or leucine (H3.3-
G34W/L) substitutions in giant cell tumor of bone (GCTB)10 have
been described, all due to mutations in H3F3A. For H3F3B,
mutations leading to a lysine-36-to-methionine (H3.3-K36M)
substitution were reported in chondroblastomas10,11. The molecular
consequence of the H3.3-K27M mutation is a global loss of the
repressive chromatin mark H3K27me3 through inactivation of the
PRC2 complex12–14. Similarly, the H3.3-K36Mmutation suppresses
the deposition of the H3K36me3 mark by interference with histone
methyltransferases nuclear receptor binding SET domain protein 2
(NSD2) and SET domain containing 2 (SETD2)11,15. Recent find-
ings suggested reduced levels of H3K36me3 and increased levels of
H3K27me3 in cis in HeLa cells overexpressing H3.3-G34W16.
However, the detailed effects of this mutant histone variant on the
epigenome are yet to be determined and to be analyzed in patients.
GCTB, where this mutation was shown as the sole alteration, offers
a unique system to study these effects in primary patient material.
GCTB is a rare locally aggressive bone neoplasm that typically
affects the meta-epiphyseal regions of long bones in young adults17.
These tumors consist of three major cell types: stromal cells origi-
nating from mesenchymal stem cells (MSC), multinuclear giant
cells and mononuclear histiocytic cells18. The GCTB stromal
cells show incidence of H3.3-G34W in more than 90% of cases
and display markers of both MSC and pre-osteoblast cell
populations10,19. The neoplastic stromal cell population secretes
high levels of the receptor activator of NF-κB ligand (RANKL) and
reduced levels of its decoy receptor, osteoprotegerin (OPG), thereby
attracting and activating surrounding monocytes. Upon activation,
the recruited monocytes fuse to form multinucleated giant cells,
which resemble osteoclasts and lead to massive bone destruction17.
Here we investigate the effects of H3.3-G34W on global epi-
genomic patterns in patient samples from four different centers.
We find epigenetic distortions that contribute to the phenotypes
of GCTB, stochastic genomic instability and increased osteolysis.
Furthermore, we demonstrate that neoplastic and non-neoplastic
GCTB stromal cells represent distinct stages of osteogenic dif-
ferentiation. Differentiation-related epigenetic differences add to
the overall picture of H3.3-G34W-associated global epigenetic
alterations, whereas the differentiation delay is potentially driven
by the direct effects of H3.3-G34W. Our findings collectively
suggest that the single-residue alteration of H3.3 induces epige-
nomic changes with implications for the development of stromal
cells and the tumorigenic process.
Results
H3K36me is unaltered in H3.3-G34W-expressing stromal cells.
Recent biochemical studies have shown that G34 substitutions in
H3.3, including G34W, inhibit the activity of the histone methyl-
transferase SETD2, which is responsible for H3K36me3, in cis (on
the same histone tail)16. We verified this effect in HEK293T cells
stably overexpressing H3.3-G34W or wild-type H3.3 as a control
and confirmed in cis effects on H3.3-G34W K36 trimethylation
levels (Supplementary Fig. 1a). We did not observe any in trans
effects on endogenous H3 modifications (Supplementary Fig. 1a), as
found for other mutant histones such as H3-K36M.
To specifically test whether these biochemical findings apply to
patient samples, we obtained access to GCTB biopsies from four
different cohorts (Supplementary Data 1). For the initial
characterization of 30 GCTB samples (Supplementary Data 1),
we performed immunohistochemical analysis with a H3.3-
G34W-specific antibody. Positive staining was observed and
validated in 29 of 30 cases (Fig. 1a, b and Supplementary Fig. 1b).
The H3.3-G34W-negative case (unified patient identifier, UPI-13)
carried a H3F3A (c.103_104GG>TT) mutation encoding a H3.3-
G34L substitution that has already been described for GCTB10
(Fig. 1b, Supplementary Fig. 1c). We established both, neoplastic,
H3.3 G34W-expressing (H3.3 MUT) and non-neoplastic, H3.3-
G34W negative (H3.3 WT) stromal cell lines from primary
tumor tissue (Fig. 1b; Supplementary Data 1). Cell type
differences were ruled out by flow cytometric analyses which
revealed a high expression of MSC markers and low expression of
hematopoietic markers in both H3.3 WT and H3.3 MUT cell
lines, suggesting that both are of mesenchymal origin (Supple-
mentary Fig. 1d). In total, we collected 96 tissue samples from 95
different GCTB patients from four different cohorts (Supple-
mentary Data 1) and were able to establish 26 stromal cell lines
from 24 different GCTB patients from two cohorts (Fig. 1c). In
addition to H3.3 WT cells, we analyzed bone marrow-derived
primary MSCs from non-GCTB patients from here on referred to
as nontumoral stromal cells (nt-SC) (Supplementary Data 1). We
verified the mutational status of the cells using Sanger resequen-
cing, ultra-deep resequencing on the MiSeq platform or whole-
genome sequencing (Supplementary Data 1, Fig. 1b, Supplemen-
tary Fig. 1c, e). In addition to the common mutation leading to
the G34W alteration in H3.3, whole-genome sequencing of seven
patient-derived primary H3.3 MUT cell lines (Supplementary
Data 1) did not reveal any recurrent genetic alterations (Fig. 1d,
Supplementary Fig. 1e, f). In contrast to other malignancies
carrying H3F3A mutations, as for example pediatric glioblastoma
with co-occurring mutations in tumor protein 53 (TP53) and
ATRX9,20 (Fig. 1e, Supplementary Fig. 1g), and to other bone
tumors, e.g., osteosarcoma (Fig. 1f, Supplementary Fig. 1h, i),
GCTB showed an extremely low overall mutation frequency for
H3.3 MUT and H3.3 WT cells (Fig. 1f, Supplementary Fig. 1e, f).
This places GCTB in a unique position to uncover epigenomic
alterations linked to H3.3-G34W.
To understand how H3.3-G34W exerts its function in tumor
cells, we analyzed protein fractions by Western Blot and found
H3.3-G34W incorporated into chromatin (Supplementary
Fig. 2a). To analyze in cis effects of H3.3-G34W in patient
derived cells, we used a specific and verified antibody to map
H3.3-G34W and identify sites of H3.3-G34W enrichment in two
independent patient cell lines (Supplementary Data 1). We
identified high-confidence genomic regions showing H3.3-G34W
enrichment (Supplementary Fig. 2b, c, Supplementary Data 2)
and profiled H3K36me3 along with several other histone
modifications using chromatin immunoprecipitation (ChIP-
mentation). Changes of H3K36me3 or H3K27me3 between
H3.3 WT and H3.3 MUT stromal cells at sites of H3.3-G34W
enrichment were minute and did not recapitulate the strong loss
of H3K36me3 in cis observed in HEK293T cells (Supplementary
Fig. 2b, c). Nucleosomes enriched by H3.3-G34W-ChIP most
probably contain H3.3-G34W, as well as wild-type H3.3
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potentially masking in cis effects on the H3.3-G34W N-terminal
tail. Using Western Blot analysis of whole cell lysates we did not
reveal any changes in the total amount of K36 methylated histone
H3 indicating that the G34W substitution does not affect
methylation of K36 on other histones lacking the mutation,
which is in line with the analysis in HEK293T cells in
Supplementary Fig. 1a (Supplementary Fig. 2d).
The epigenome of H3.3 MUT cells is globally altered. As the
effects of H3.3-G34W on the global level of H3.3K36me3 were
insignificant, we tested whether H3.3-G34W might exert its
tumorigenic effects through other epigenetic mechanisms. We
analyzed several H3.3 MUT and H3.3 WT cells, as well as a large
number of biopsies of the four GCTB cohorts (Supplementary
Data 1), using HumanMethylation450 arrays (89 samples in total)
UPI-13 UPI-14 UPI-15 UPI-16 UPI-17 UPI-18 UPI-19 UPI-20









































































BOCA (N = 10)G34-mutant PGBM (N = 10)
2468 1 0 3 3 1 0 2468
GCTB (N = 9)












































































Fig. 1 Initial characterization of GCTB patient samples. a Immunohistochemical staining of primary GCTB tumor resections with a H3.3-G34W-specific
antibody (Active Motif) (red). UPI, unified patient identifier. The scale bar exemplarily shown for UPI-30 indicates 500 µm. b Quantification of the mutation
at position 103 in the H3F3A gene (c.103G>T) leading to the H3.3 G34W substitution in tumor resections (dark gray) and derived stromal cell lines (light
gray) using deep targeted resequencing. VAF, variant allele frequency. c Overview of GCTB tissues and derived stromal cell lines (H3F3A wt in blue, mut in
red, non-tumoral stromal cells (nt-SC) in violet) analyzed within this study. IHC, immunohistochemistry; WGS, whole genome sequencing; WGBS, whole
genome bisulfite sequencing; 450 K, DNA methylation array. d–f Circos plot of recurrent structural variants in GCTB (d), H3.3-G34R-baring pediatric
glioblastoma (PGBM, e) and bone cancer (BOCA-UK, f), cohorts based on whole genome sequencing data. Green lines represent translocations, blue lines
deletions, red lines duplications, and black lines inversions. The variant recurrences are represented by bar plots. The outermost layer represents functional
small variants (SNVs and small indels). The middle layer represents copy number variations. The innermost layer represents structural variations. All layers
are normalized to the compared cohort size. Osteosarcoma cohort was sub-sampled at random to the size of the other two cohorts. See high-resolution
versions in Supplementary Fig. 1f–h.
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and observed full-range DNA methylation changes of a large
number of CpG sites (Fig. 2a). Dimensionality reduction and
clustering analysis of the methylation data showed the most
pronounced changes between primary patient-derived H3.3 MUT
and H3.3 WT cell lines as compared to GCTB biopsies. Most of
the primary tumor samples had an intermediate methylome
identifying them as mixtures of normal and tumor cells (Fig. 2a,
b), as also confirmed by deep resequencing of the H3F3A gene
locus of tissue-derived DNA showing a lower variant allele fre-





















































































































































Fig. 2 Genome-wide epigenetic distortion in H3.3 MUT stromal cells. a HumanMethylation450 profiles of GCTB tumor tissue samples (green), GCTB
stromal cells (GCTB-SC in pink, wt in blue, mut in red) and healthy nontumoral stromal cells (nt-SC, violet). Heatmap displays 10,000 CpG sites with
highest variance across all samples. Agglomerative, hierarchical clustering of rows (CpGs) and columns (samples) was performed with average-linkage
based on Euclidean distance metric. b Principal component analysis of HumanMethylation450 array-based DNA methylation profiles of GCTB tumor tissue
(triangles), GCTB stromal cells (GCTB-SC, circles) and nontumoral stromal cells (nt-SC, rectangles). Samples with wildtype (wt) and mutant (mut) H3F3A
status are shown in blue and red, respectively. Each data point represents one patient. c–e Hierarchical clustering with correlation distance of DNA
methylation (c), chromatin accessibility (d) and H3K27me3 (e) profiles in nt-SC (violet) and stromal cells (pink). H3.3 mutational groups in blue (H3.3
WT) and red (H3.3 MUT). Heatmaps represent pairwise Pearson correlation coefficients (r) between respective modification profiles of two cell lines.
Dendrograms were obtained with agglomerative hierarchical clustering with 1-r distance and average linkage. Heatmap color codes represent the H3.3
mutational status (inner), and the cell type (outer). UPI, Unified patient identifier. f Stratification of epigenetic differences using MSC-specific chromatin
states as defined by ChromHMM. For DNA methylation difference between average methylation levels of all CpGs falling into corresponding states in H3.3
WT and H3.3 MUT cells is presented. For chromatin accessibility and histone post-translational modifications (PTMs), the standardized difference (delta
over root-mean-square of deltas in each row) between average normalized read counts over all regions of a state is shown (values are only row-wise
comparable). Mnemonics for the ChromHMM states are defined by the Roadmap project (TssA, active TSS; TssFlnk, active TSS flanking regions; Tx,
transcribed regions; TxFlnk, transcription franking regions; TxWk, weakly transcribed regions; Enh, enhancers; EnhG, genic enhancers, ZNF/Rpts; zinc
finger genes and repeats; TssBiv, bivalent TSS; BivFlnk, flanking bivalent regions; EnhBiv, bivalent enhancer; ReprPC, Polycomb repressed; ReprPCWk, weak
Polycomb repressed; Quies, quiescent). All analyzed stromal cell lines with their UPIs are listed in Supplementary Data 1.
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mutation (Fig. 1b). This observation prompted us to restrict all
our subsequent analyses to H3.3 MUT and H3.3 WT cells in
order to obtain a clean view of H3.3-G34W-associated epigenetic
alterations in pure cell populations. To further a detailed analysis
of the epigenome, we profiled DNA methylation at single CpG
resolution using whole genome bisulfite sequencing (WGBS),
analyzed chromatin accessibility with the assay for transposase-
accessible chromatin using sequencing (ATAC-seq) and analyzed
global distribution of several histone marks (H3K4me1,
H3K4me3, H3K9me3, H3K27me3, H3K27ac, H3K36me3) to
investigate their potential redistribution. Since the initial methy-
lation analysis showed high homogeneity within the mutant and
wild-type groups and culturing primary tumor cells did not yield
sufficient material for a comprehensive omics profiling of each
line, we analyzed H3.3 WT and H3.3 MUT cell lines from several
patients to exclude patient-dependent alterations (Supplementary
Data 1). Global hierarchical clustering proved the H3.3-G34W
substitution to be the major determinant of variability in DNA
methylation, chromatin accessibility and posttranslational histone
modifications (H3K27me3, H3K27ac, H3K4me1) with H3.3
MUT and H3.3 WT groups forming separate clusters (Fig. 2c–e,
Supplementary Fig. 2e). In contrast, other histone modifications
(H3K36me3, H3K4me3) did not result in H3.3 MUT-separating
and H3.3 WT-separating clusters (Supplementary Fig. 2e). Since
nt-SCs clustered with H3.3 WT cells, we combined all H3.3 wild
type cells into a single control group (H3.3 WT) for further
analysis.
In order to identify loci with more pronounced epigenetic
changes, we used a genome-wide approach to stratify the
observed differences from all epigenetic layers using the
ENCODE functional annotation of the MSC epigenome21. We
observed profound differences in several groups of chromatin
states including heterochromatic and Polycomb-repressed states,
as well as bivalent domains (Fig. 2f). Heterochromatic regions
were noticeably hypomethylated while bivalent domains accu-
mulated a whole range of alterations, including gain of DNA
methylation, loss of chromatin accessibility, as well as loss of
several histone modifications (H3K27me3, H3K4me3 etc).
Collectively, we conclude that the epigenome of H3.3
MUT cells shows significant and reproducible differences to that
of H3.3 WT stromal cells.
Hypomethylation in megabase domains and genomic
instability. We first followed up changes associated with loss of
DNA methylation. In contrast to the homogeneity of DNA
methylation profiles observed within each of the two groups
(Supplementary Fig. 3a), DNA methylation was non-uniformly
altered between H3.3 WT and H3.3 MUT cells across the entire
genome (Fig. 3a). The majority of significantly changed loci
showed profound reduction of DNA methylation in H3.3
MUT cells, while a minority was hyper-methylated (Fig. 3a,
Supplementary Fig. 3b). Overall, H3.3 MUT cells exhibited a 20%
genome-wide reduction of DNA methylation (Fig. 3b, Supple-
mentary Fig. 3c). To systematically characterize the abundant
DNA methylation changes, we segmented the genome into large
methylation domains (LMD I to IV) with sizes >20 kb (Supple-
mentary Fig. 3d, Supplementary Data 2) using a combination of
breakpoint analysis and clustering (see Methods for details). The
majority of regions (predominantly LMDs III and IV) matched
the criteria for partially methylated domains i.e., megabase-scale
domains of predominantly repressive chromatin with low gene
density22. Each LMD had a distinct level of DNA methylation, a
discrete pattern of histone marks and gene density, suggesting
different functional roles (Fig. 3c–e). For instance, LMD III
showed enrichment of H3K27me3, while LMD IV was associated
with H3K9me3, suggesting an association with facultative and
constitutive heterochromatin (Fig. 3e). Furthermore, LMD III
domains were often detected as flanking to LMD IV. LMDs I to
IV showed decreasing average methylation levels starting from
over 0.75 down to less than 0.25 (Fig. 3c). Lowly methylated
LMDs III and IV which could be characterized as heterochro-
matic (Fig. 3e) showed the most pronounced demethylation
comparing H3.3 MUT cells to H3.3 WT cells. We concluded that
global DNA methylation alterations in GCTB are non-uniformly
distributed along the genome, and that the most pronounced
global changes take place in large-scale domains associated with
facultative and constitutive heterochromatin, roughly corre-
sponding to LMDs III and IV.
We next sought to associate hypomethylation with other
epigenetic alterations. Consistent with the global loss of DNA
methylation, we observed increased chromatin accessibility in the
H3.3 MUT cells with approximately 1.5-times more gained than
lost differential ATAC-seq peaks (Fig. 3f, Supplementary Data 3).
ATAC peaks gained in H3.3 MUT cells were overrepresented in
the LMDs III and IV (Fig. 3g) indicating a more open state in
respective genomic segments. These LMDs also showed strong
reduction in the heterochromatic histone mark H3K9me3
(Fig. 3h). Examples of changes in different LMDs can be seen
in Fig. 3i. The ATAC peaks gained in H3.3 MUT showed a
significant overlap with repetitive elements such as long
intersperse nuclear elements (LINE), short interspersed nuclear
elements (SINE) and long terminal repeat (LTR) elements which
are normally silenced by DNA methylation (Supplementary
Fig. 3e, Supplementary Data 3). Looking at other known
repetitive regions, such as centromeres and telomers, we found
them to be affected by the genome-wide hypomethylation
(Supplementary Fig. 3f). Multicolor fluorescence in situ hybridi-
zation (m-FISH) analysis found H3.3 WT cells to have a normal
karyotype, while H3.3 MUT cells in contrast displayed different,
non-recurrent centromeric fusions which could be a potential
consequence of the heterochromatin defects described above
(Supplementary Fig. 3g). We conclude that H3.3-G34W associ-
ates with heterochromatic defects that potentially contribute to a
genomic instability previously described as characteristic for
GCTB23.
Isogenic cells recapitulate H3.3 MUT DNA hypomethylation.
As H3.3 MUT stromal cells showed the strongest epigenetic
differences to H3.3 WT stromal cells on the DNA methylation
level, we expected DNA methylation to play a major role in
stromal cell transformation leading to GCTB. To verify that the
observed epigenetic changes were dependent on H3.3-G34W
expression, we aimed to recapitulate the findings in an unrelated
cell line system. To this end, we introduced the H3.3-G34W
encoding mutation into HeLa cells by targeting the endogenous
H3F3A locus as earlier described (Supplementary Fig. 4)24.
Individual iso-H3.3-WT and iso-H3.3-G34W clones were iso-
lated, of which four iso-H3.3-WT and four iso-H3.3-G34W
monoclonal lines and one parental HeLa cell line were subjected
to HumanMethylationEPIC DNA methylation analysis (Fig. 4a).
The iso-H3.3-G34W samples showed similar alterations as
those found when comparing H3.3 MUT and H3.3 WT stromal
cells of GCTB (Fig. 4a–e). Principal component analysis of the
most variable methylation probes clustered iso-H3.3-WT clones
together while iso-H3.3-G34W clones dispersed off, indicating
changes in DNA methylation in iso-H3.3-G34W but not WT
isogenic cell lines (Fig. 4a). Similar to primary GCTB cells, the
largest principal component (PC1, 31% of variance explained)
captured widespread hypomethylation in iso-H3.3-G34W
accompanied by focal hypermethylation events (Fig. 4a).
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Clustering analysis further enforced the distinct difference
between iso-H3.3-WT and G34W clones (Fig. 4b). A scatter plot
of all probes indicated that iso-H3.3-G34W cells showed pre-
dominantly hypomethylation as also shown for H3.3 MUT cells
from GCTB (Fig. 4c). We found 9047 differentially methylated
probes (Δ β-value>0.2 and FDR < 0.05) of which 5688 (63%) were
hypomethylated in iso-H3.3-G34W cells (Fig. 4d). These data
recapitulate the bias towards hypomethylation found in H3.3
MUT stromal cells in comparison to H3.3 WT stromal cells
(compare Fig. 3a, b), and confirm that the changes in DNA
methylation are associated with H3.3-G34W. CpG sites that lost
methylation were more frequently localized in intergenic regions
and promoter-proximal exons, while hypermethylated ones were
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Fig. 3 Heterochromatin defects in H3.3 MUT stromal cells. a Binned scatterplot of DNA methylation profiles fromWGBS of H3.3 WT cells (x-axis) versus
H3.3 MUT cells (y-axis). Hexagon color represents binned density gradient of 1 (blue), 1000 (yellow), and 106 (red). b Genome-wide mean level of DNA
methylation in H3.3 WT (blue) and H3.3 MUT (red) cells. Each data point represents one patient, H3.3 WT n= 4 and H3.3 MUT n= 7 biologically
independent cell lines. The difference is statistically significant (p= 8.3 10−3, unpaired two-tailed t-test). c Methylation level distribution at large
methylation domains (LMDs) in H3.3 WT (blue) and H3.3 MUT (red) cells. Each point represents a single LMD segment. d Mean gene density of LMDs.
MB, mega bases. e Normalized levels of histone modifications at LMDs in H3.3 WT cells. Heatmap represents z-scores of average signals across all
segments within the LMDs calculated using overall mean level and standard deviation across all LMD segments. f Absolute numbers of ATAC-seq peaks
with differential chromatin accessibility between H3.3 WT cells and H3.3 MUT cells. Lost (light gray) and gained (dark gray) refer to peaks showing a
decrease (disappearance) or increase (emergence) in H3.3 MUT cells, respectively. g Stratification of differential chromatin accessibility between H3.3 WT
and H3.3 MUT cells by overlap with LMDs. Labels as in f; all, distribution of ATAC peaks across all LMDs. h Changes of histone modifications between
H3.3 WT and H3.3 MUT stromal cells at LMDs. Heatmap represents standardized difference (delta over root-mean-square of all deltas in each column)
between average normalized read counts over all regions of a state is shown (values are only column-wise comparable). i Genomic browser view of WGBS,
H3K9me3 ChIP-seq and ATAC-seq in a representative 7Mbp region on chromosome 14 (96,000,000–103,000,000). Tracks represent average profiles
for H3.3 WT (blue) and H3.3 MUT (red) cells. Bottom panel indicates gene locations based on the UCSC default gene track. Differential ATAC-seq labels
as in f. All analyzed stromal cell lines with their UPIs are listed in Supplementary Data 1. In all boxplots th bars represents the means, boxes the IQRs, upper
and lower whiskers extend from the smallest to the largest value within 1.5 IQR from the lower and upper edges of the box, respectively.
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exons (Fig. 4e). This was coherent with widespread hypomethy-
lation of intergenic regions (LMDs III and IV in Fig. 3c, d, e, h)
and overrepresentation of promoters among hypermethylated
regions (Supplementary Fig. 3b) observed in H3.3 MUT cells. A
specific example for a hypomethylated region in iso-H3.3-G34W
cells is the RANKL locus showing hypomethylation at exon 3, a
potential alternative promoter element (Fig. 4f). This is in line
with the methylation differences observed between H3.3 WT and
H3.3 MUT stromal cells at the same locus (Fig. 5a). RANKL
signaling has been extensively studied in GCTB25. The expression
of RANKL, a master regulator of osteoclast differentiation26, has
been shown to be upregulated in GCTB stromal cells causing an
osteolytic phenotype25. We verified the increased expression of
RANKL (TNFSF11) in H3.3 MUT cells (Fig. 5b, Supplementary
Fig. 5a) and additionally observed decreased expression and se-
cretion of its decoy receptor Osteoprotegerin (OPG, TNFRSF11B)
(Fig. 5c, Supplementary Fig. 5a, b). Similar expression patterns
were already described by us earlier24. The OPG locus showed
decreased levels of the active histone marks H3K4me3 and
H3K27ac potentially indicating a missing activation by a tran-
scription factor (Supplementary Fig. 5c). One known transcrip-
tion factor of OPG is the early B-cell factor 2 (EBF2)27,28 which is
a bivalent gene (Fig. 5f) and belongs to the key regulators of
osteogenic differentiation in mice29. OPG became downregulated
after siRNA mediated EBF2 knockdown, confirming a role of
EBF2 in OPG expression in stromal cells (Fig. 5d, Supplementary
Fig. 5d). The EBF family is a conserved group of four tran-
scription factors. Our RNA-seq analysis found EBF2 and EBF3 to
be differentially expressed between H3.3 WT and H3.3 MUT
stromal cells (Fig. 5e, Supplementary Fig. 5e). EBF3, previously
reported as a tumor suppressor in glioblastoma30,31, showed
reduced expression in H3.3 MUT cells whereas EBF2 expression
was almost completely lost. We found the EBF2 locus to be
hypomethylated with a focal hypermethylation around the pro-
moter region (Fig. 5f). Increased H3K9me3 and H3K27me3 levels
and decreased levels of H3K27ac supported a repressed state of
EBF2. Lost ATAC signals in H3.3 MUT cells indicated differen-
tially closed chromatin. These findings link the H3.3 G34W-
associated epigenetic dysregulation of EBF2 expression to the
osteolytic phenotype of GCTB.
Taken together, we showed that the stable introduction of
H3.3-G34W into a GCTB unrelated cell line recapitulates the
DNA hypomethylation trend seen in GCTB stromal cells.
Furthermore, we could detect epigenetic alterations that directly
and indirectly affected the expression of key regulators of bone
metabolism shedding novel light on the emergence of the
osteolytic phenotype in GCTB.
Bivalent promoters and delayed differentiation in H3.3 MUT.
Besides dominant hypomethylation in heterochromatic regions,




















































































Fig. 4 Recapitulation of DNA methylation alterations in an isogenic system. a Principal component (PC) analysis of HumanMethylationEPIC profiles of
parental (green triangle), iso-H3.3-WT (blue rectangles) and iso-H3.3-G34W (red circle) HeLa cells. Each data point represents an independent clone.
bMethylation levels of top 2000 probes associated with each of the first three principal components in one parental (green), four iso-H3.3-WT (blue) and
four iso-H3.3-G34W cells (red). c Scatter plot of average individual CpG probe methylation of four iso-H3.3-WT (x-axis) vs. four iso-H3.3-G34W (y-axis)
clones. Color dots indicate incremental delta means of methylation, with orange representing >0.5 delta-mean. d Fractions of HumanMethylationEPIC
probes differentially methylated between iso-H3.3-G34W and iso-H3.3-WT HeLa cells, by direction of DNA methylation change (light
gray–hypomethylation, dark gray–hypermethylation). e Enrichment (positive values) or depletion (negative values) of major gene model features among
differentially methylated probes. OR, odds ratio. f Genome browser snapshot displaying DNA methylation levels of CpGs in the vicinity of the TNFSF11 locus
in parental (green), iso-H3.3-WT (blue) and iso-H3.3-G34W cells (red). Points represent methylation values of individual CpGs and the lines depict LOESS
curves with degree 1 and span 0.5.
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domains (Fig. 2f), which are well known sites of H3.3
deposition5,32. Changes included gain of DNA methylation which
coincide with decreased accessibility, decrease of H3K27me3 and
increased levels of H3K36me3 (Fig. 2f). Most promoter-
associated ATAC peaks that were lost in H3.3 MUT cells over-
lapped with bivalent promoters (Supplementary Fig. 6a). As a
consequence of epigenetic disturbance, bivalent genes comprised
a significant portion of differentially expressed genes both upre-
gulated and downregulated in H3.3 MUT cells (Supplementary
Fig. 6b). It was previously reported that comparable epigenetic
and transcriptional perturbations at bivalent genes occur in H3.3-
deficient mouse ESCs7. Genes with decreased expression in H3.3
MUT were significant enriched in Polycomb-target genes,
including several developmental transcription factors (Supple-
mentary Fig. 6c, Supplementary Data 4). This was also supported
by genomic overlap enrichment analysis of lost ATAC peaks
showing strong enrichment at regions where binding of polycomb
repressive complex 2 (PRC2) components enhancer of zeste 2
(EZH2) and suppressor of zeste 12 (SUZ12) was found in
numerous cell lines (Supplementary Fig. 6d, Supplementary
Data 3). Gene ontology (GO) analysis of closed regions revealed
many categories related to differentiation (Supplementary
Fig. 6e). Impaired differentiation was already suggested for tumor
entities harboring mutations in histones including GCTB15,33. To
investigate whether H3.3 WT and H3.3 MUT cells differ in their
osteogenic differentiation state, we performed a comparison
across all genes covered by RNA-seq with those obtained from an
in vitro differentiation of MSCs. The expression changes during
osteogenic differentiation largely correlated inversely with the
expression changes observed between H3.3 WT and H3.3
MUT cells, with anticorrelation increasing from very early to late
differentiation stages (Fig. 6a). Accordingly, an overlap of the
differentially expressed genes from both experiments showed that
the majority of matches were upregulated during differentiation
and downregulated in H3.3 MUT cells (Supplementary Fig. 6f).
Examples included insulin growth factor 2 (IGF2) and leptin
(LEP) previously implicated in osteogenic differentiation34,35






























































































































































Fig. 5 The epigenetic determinants of the osteolytic phenotype in GCTB. a Genome browser view of the gene TNFSF11 encoding for RANKL. Each lane
(dash-separated) represents normalized averaged signals of DNA methylation (WGBS), the level of H3K4me3, H3K4me, H3K9me3, H3K27ac, H3K27me3,
H3K36me3, and chromatin accessibility (ATAC) in several replicates of H3.3 WT (lane-wise top) or H3.3 MUT (lane-wise bottom) cells. b, c Expression
levels of RANKL (TNFSF11) and OPG (TNFRSF11B) in H3.3 WT (blue) H3.3 MUT (red) cells as analyzed by RNA-seq. TPM, transcripts per million.
Differences were borderline significant for both genes with p= 0.092 (TNFSF11) and p= 0.062 (TNFRSF11B), Wilcoxon rank sum test with n= 6
independent patient cell lines in each group. d Expression analysis of EBF2 and OPG (TNFRSF11B) by qRT-PCR 48 h after siRNA-mediated knockdown of
EBF2 in H3.3 WT cells (UPI-13). Log fold change (LFC) relative to expression in cells transfected with control siRNAs. n= 4 independent experiments are
shown. Results showed significance in a one-sample t-test with p-values 0.006 and 0.018. e Expression levels of all members of the EBF family in H3.3 WT
(blue) H3.3 MUT (red) cells as analyzed by RNA-seq. TPM, transcripts per million. Differences were significant for EBF2 (p= 4.8 × 10−3) and EBF3 (p=
2.1 × 10−3), Wilcoxon rank sum test with n= 6 independent patient cell lines in each group. f Genomic browser view of the EBF2 locus. Legend as in a. All
analyzed stromal cells with their UPIs are listed in Supplementary Data 1. In all boxplots bar represents the mean, box the IQR, upper and lower whiskers
extend from the smallest to the largest value within 1.5 IQR from the lower and upper edges of the box, respectively.
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differentiated state of H3.3 MUT cells resembling MSC in a very
early stage of differentiation and H3.3 WT cells showing an
expression profile more similar to MSC in early to middle stage of
osteogenic differentiation (Fig. 6b). To confirm differences in the
osteogenic differentiation state, we stained H3.3 WT and H3.3
MUT stromal cells for the activity of the osteogenic marker
alkaline phosphatase (ALP). Most of the H3.3 WT cells exhibited
ALP activity whereas only some H3.3 MUT cells showed ALP
activity (Fig. 6c). Quantification of the ALP activity relative to
viability as a surrogate for cell count confirmed reduced ALP
activity for H3.3 MUT stromal cells (Fig. 6d). Impaired differ-
entiation of GCTB stromal cells was suggested earlier based on
the analysis of histological markers36 and transcriptomic profil-
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Fig. 6 Delay of osteogenic differentiation in H3.3 MUT stromal cells. a Correlation between differentiation-ssociated and H3.3-G34W-associated gene
expression changes. For the differentiation log-fold changes (LFC) were calculated between average of profiles from each differentiation timepoint group
(very early: 0.5 to 2 h; early: 4 to 554 16 h, mid: 24 to 168 h; and late: 336 to 504 h) and the profiles of mesenchymal stem cells (MSCs) sampled prior to
the start of the experiment. Each hexagon reflects the density of the underlying data points. Genes with most pronounced changes in both data sets are
marked. b Principal component analysis of RNA-Seq data from osteogenic differentiation of MSC (greyscale rectangles) and expression profiles of GCTB
samples, H3.3 WT (blue triangles) and H3.3 MUT (red circles), only PC2 and PC3 are shown, while PC1 capturing batch effects between two experiments
is not shown. The sampled differentiation timepoints were grouped as in a. For H3.3 WT and H3.3 MUT each data point represents one patient. The
isochores and background shading give a surface fit-based estimate of differentiation time for each point of the (PC2, PC3) plane. c Alkaline phosphatase
staining of nt-SC, H3.3 WT, and H3.3 MUT cells during osteogenic differentiation. d Quantification of alkaline phosphatase (ALP) activity relative to the
viability as a surrogate for cell count over the time course of 15 days of in vitro osteogenic differentiation. Each data point represents one patient. Middle
bars represent means, error bars show standard deviations within each group. H3.3 WT in blue, n= 8 and H3.3 MUT in red, n= 7 biologically independent
cell lines from different patients. P-values are from unpaired (for within-group comparisons) and paired (for between-group comparisons) two-tailed t-
tests. e. Model for GCTB tumorigenesis: The H3F3A mutation encoding H3.3-G34W occurs in osteoblastic precursor cells and leads to alterations in
osteogenic differentiation. Epigenetic differences described between H3.3 WT and H3.3 MUT stromal cells are the result of measuring cells at different
differentiation stages and direct effects of the mutated histone.
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and H3.3 WT cells from several patients in vitro to analyze the
potential of H3.3 MUT and H3.3 WT cells to differentiate. While
both H3.3 WT and H3.3 MUT stromal cells showed an increase
of ALP activity indicating the potential for osteogenic differ-
entiation (Fig. 6c, d), we noticed that H3.3 MUT stromal cells
lagged behind and did not achieve the level of ALP activity
reached by H3.3 WT stromal cells (Fig. 6c, d). We concluded that
H3.3-G34W associates with changes in bivalent regions and that
their deregulation potentially has an effect on osteogenic differ-
entiation. H3.3 WT and H3.3 MUT stromal cells therefore differ
in their state of osteogenic differentiation in GCTB patients and
this difference contributes to the herein found epigenetic altera-
tions (Fig. 6e).
Discussion
Mutant epigenetic regulator proteins, including histones, have
been described in multiple cancer types2. Despite the fact that
oncogenic mutations in histones influence the epigenetic land-
scape, deep insight into the mechanistic ramifications to cancer
initiation is still incomplete. Several studies investigated the
mechanism of how the G34W substitution in histone variant
H3.3 affects the epigenetic machinery responsible for its post-
translational modifications. To this end, reduced H3K36 methy-
lation and increased H3K27me3 in cis were described in model
systems and verified by us in this work16,38. However, whether
these effects can be found in patients and whether epigenetic
changes are involved in tumorigenesis of GCTB was not known
so far. In this paper, we therefore analyzed GCTB tissue, as well as
patient-derived primary stromal cells from four different centers
to investigate H3.3-G34W-associated epigenetic changes and
their contribution to the GCTB neoplasia. The high incidence of
H3.3-G34W in GCTB in a largely unaltered genomic context
leaves GCTB as a suitable system to study histone mutation-
driven tumorigenesis.
We found that, despite that H3.3-G34W is incorporated into
chromatin, its presence did not lead to changes in the global
amount of H3K36me3 as shown for other substitutions affecting
H3.3 lysine 27 and lysine 3611,13,39. This ruled out a possible in
trans effects of H3.3-G34W on histone posttranslational mod-
ifications. Using ChIP sequencing, we identified high confidence
H3.3-G34W enrichment sites in patient cell lines and analyzed
common histone marks at these regions. No pronounced differ-
ences were found that could recapitulate the in cis effects on H3.3
lysine methylation observed in HEK293T cells. The absence of
clear-cut in cis effects upon chromatin modifications could be
explained by an inability to distinguish wild-type and mutant
H3.3 in GCTB samples by western blot analysis. In ChIP analysis,
nucleosomes of mutant cells could include both, wild-type, as well
as mutated H3.3 obliterating possible in cis effects. Moreover,
antibodies against histone modifications cannot distinguish
between H3 variants and the overall small fraction of the mutant
H3.3 (25% of overall H3.3) in the total H3 pool makes analysis of
H3.3 modifications challenging.
We show that H3.3-G34W, the sole recurrent alteration of
GCTB, associates with large-scale differences in multiple epige-
netic marks. H3.3 MUT stromal cells show heterochromatic
defects, specifically reduced genome-wide levels of DNA methy-
lation and gained accessibility at heterochromatic regions which
is in line with previous reports on pediatric glioblastomas with
the G34R substitution in H3.339. These changes could potentially
contribute to the genomic instability described for GCTB23. We
furthermore observed localized changes at bivalent regions, some
of the same sites previously described as targets of H3.3
deposition5,7. DNA methylation changes could be recapitulated
using an isogenic system verifying effects on the methylome to be
H3.3-G34W-specific. Moreover, we show H3.3-G34W-associated
methylome changes to directly or indirectly affect the expression
of the main players of bone metabolism, RANKL and OPG. These
results connect the H3.3-G34W-associated epigenetic dysregula-
tion to the osteolytic phenotype, a hallmark of GCTB.
While the epigenomic differences between H3.3 WT and H3.3
MUT stromal cells can be partially ascribed to direct effects of
H3.3-G34W, other alterations observed can be explained by the
fact that H3.3 MUT and H3.3 WT stromal cells represent distinct
differentiation stages. Assuming epigenetic reprogramming dur-
ing differentiation as demonstrated in recent studies40,41, this
could also contribute to the epigenetic differences seen between
H3.3 WT and H3.3 MUT cells. While expression profiles from
H3.3 MUT cells resemble precursor states of osteoblasts, the H3.3
WT cells resemble more mature osteoblasts, suggesting impaired
or delayed differentiation of H3.3 MUT cells as already suggested
by42. A weak differentiation signature is in line with previous
reports suggesting that neoplastic GCTB stromal cells are
expressing markers of an early osteoblastic differentiation43.
Genes such as IGF234, LEP, and stathmin-like 2 (STMN2), found
to be downregulated in H3.3 MUT stromal cells, were described
to play a role in mesenchymal stem cell differentiation and
osteoclastogenesis in mice, in promoting bone differentiation35
and as a marker for osteogenesis44, respectively. Consistently,
H3.3 was found to be closely associated with differentiation
processes7,45,46. The impairment of differentiation of H3.3 MUT
stromal cells could be mediated by H3.3-G34W-associated
downregulation or prevention of induction of genes upregulated
during osteogenic differentiation through a yet unknown
mechanism. Epigenetic repression of bivalent genes and dysre-
gulation of PRC2 targets described in this study could potentially
contribute to the observed phenotype. H3.3 MUT stromal cells
are still able to undergo osteogenic differentiation, as it was also
found in studies not separating H3.3-mutant neoplastic from
H3.3-wild-type stromal cells of GCTB tissue47,48.
Direct effects of H3.3-G34W upon the epigenome could be
confirmed in isogenic HeLa cells. The effects on DNA methyla-
tion were less pronounced in HeLa cells compared to the
alterations observed comparing H3.3 WT and H3.3 MUT stromal
cells, potentially reflecting the relatively small passage number
after the introduction of the H3F3A mutation (approximately 20
passages) in the HeLa cells compared to primary cells. Another
explanation may be that DNA methylation differences between
H3.3 WT and MUT stromal cells largely reflect differentiation-
associated epigenomic alterations shown to occur during osteo-
genesis41 as discussed above. A detailed analysis of H3.3-G34W-
induced effects on the epigenome and their connection to
impeded osteogenic differentiation will require systems capable of
reproducing the differentiation context in vitro or in vivo, such as
MSC-derived immortalized cell lines or animal models. Alter-
natively, detailed transcriptomic and epigenomic maps of the
osteogenic differentiation can be instrumental for delineating
H3.3-G34W-induced and differentiation-related alterations.
Furthermore, meticulous computational approaches, e.g.,49, may
help disentangle differentiation-related from cancer-specific epi-
genetic alterations.
Taken together, our results suggest that the molecular
mechanism behind H3.3-G34W-induced epigenomic alterations
and neoplastic transformation in GCTB is different to the action
of other mutant histone variants such as H3.3-K27M and H3.3-
K36M, where the mutated amino acid is a direct target for histone
modification11,13,15. This suggests that the H3.3-G34W substitu-
tion alters the N-terminal interactome as previously described24,
recruiting novel binders or disrupting interactions with binders.
The described DNA methylation changes can be indicative of
H3.3-G34W affecting either the binding or the activity of
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enzymes writing (DNA methyltransferases, DNMTs) or erasing
(ten eleven translocators, TETs) this modification. On the
structural side it is known that DNMT3a/b recognize H3K36me3
with their PWWP-domains50,51. The G34W substitution might
interfere with binding of DNTM3a/b PWWP preventing proper
establishment of DNA methylation patterns. The thereby induced
remodeling of the epigenome associated with H3.3-G34W, in
particular changes at heterochromatic and bivalent regions, could
contribute to an impaired osteogenic differentiation and the
phenotypes of GCTB: stochastic chromosomal rearrangements
and increased RANKL signaling. Precise sequences of molecular
events leading to these phenotypes will be a matter of further
studies.
Methods
Patient samples. Biopsies and derived primary cell lines were obtained from
patients in the Orthopedic University Hospital, Heidelberg (UHOK), the Korean
Cancer Center (KCC), the University Clinic of Leipzig (UKL) and the University
Medical Center Hamburg-Eppendorf (UKHE). The complete list of samples used
in the study is available in Supplementary Data 1. The use of patient samples and
the experiments performed in this study was approved by and in accordance with
guidelines and regulations by the Ethics Committees of the University of Heidel-
berg, University Clinic of Leipzig, University Medical Center Hamburg-Eppendorf,
and the National Cancer Center of Korea (IRB NCC2015-0070). Informed consent
has been obtained from all patients. All H3.3 WT and H3.3 MUT cells analyzed in
the manuscript were obtained from different patients or indicated as relapse
samples by addition of ‘.2’ to the UPI.
Isolation of GCTB stromal cells from patient tissue. Tumor tissue from surgical
resections was mechanically cut into small pieces and digested with 1.5 mg/ml
collagenase B (Roche Diagnostics, Mannheim, Germany) at 37 °C for 3 h in Dul-
becco’s Modified Eagle Medium (DMEM) (Lonza GmbH, Wuppertal, Germany)
high glucose supplemented with 10% fetal calf serum (FCS) (Biochrom, Berlin,
Germany), and 100 U ml−1 penicillin/streptomycin (Lonza GmbH). Cells were
collected by centrifugation, washed twice in PBS and cultured in DMEM as
described above. Twenty-four hours after plating, cells were carefully treated with
Trypsin/EDTA (Lonza GmbH) leaving the giant cells attached in the culture flask.
Detached cells were cultured for further 2 passages to eliminate histiocytes and
remaining giant cells.
Isolation of nt-SC cell lines from the bone marrow. Nt-SCs were isolated from
fresh bone marrow samples derived from the iliac crest under the approval of the
Ethics Committee of the University of Heidelberg. Bone marrow cells were purified
on a Ficoll-Paque™ Plus density gradient (GE Healthcare, München, Germany),
washed in PBS and treated with erythrocyte lysis buffer (0.154M NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA) to remove erythrocytes. The nt-SC-enriched fraction was
seeded and cultured in DMEM high-glucose supplemented with 12.5% FCS
(Biochrom), 2 mM L-glutamine, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin
(Lonza), 4 ng/ml basic fibroblast growth factor (Merck Chemicals GmbH, Darm-
stadt, Germany, 50 μM 2−mercaptoethanol and 1% non-essential amino acids
(Invitrogen, Karlsruhe, Germany). After 48 h, cultures were washed with PBS to
remove non-adherent material. During expansion, medium was replaced twice
a week.
Cell line maintenance. The GCTB stromal and nt-SC cell lines were cultivated in
DMEM/F12 no phenol red (Gibco, Invitrogen, Life Technologies, Paislay, UK)
supplemented with 10% FCS (Biochrom, Berlin, Germany) and 2 ng μl−1 basic
FGF (Biolegend, San Diego, USA) at 37 °C and 5% CO2. To avoid contact inhi-
bition, cells were split after reaching maximum 90% of confluency.
Commercially available cell lines. All commercially available cell lines used
within this work were authenticated: Hos143B: DSMZ 09/2018, full matching STR
reference profile; CAL-72: COA Multiplexion 09/2018; identity based on a SNP-
based assay 100%; HEK293T: COA Multiplexion 06/2020, identity based on a SNP-
based assay 100%; HeLa: Korean Cell Line Bank, COA 03/2018, full matching STR
reference profile.
Isogenic cell lines. The establishment of H3.3-GFP isogenic cell lines in HeLa cells
utilized the zinc-finger (ZF) targeting methodology24. Cells were transfected with
the two zinc finger subunits-encoding vectors pAC HA nIL2RGL hNeeai_1140 and
_1141 and the targeting constructs containing the cDNA sequence of H3F3A
ligated into the pBluescript II (SK-) vector together with an in-frame eGFP locus
and IRES separating Neo-selection cassette by NEPA21 (Nepa Gene Co. Ltd.)
electroporation. Subsequently, the cells were cultured in media under neomycin
selection using G418 for four weeks. Surviving cells were FACS-sorted and
individual clones were allowed to propagate. HEK293T were lentivirally-
transduced with human H3.3-HA-3XFLAG constructs in pLVX expression vectors
and selected with puromycin. Cells were maintained in DMEM (Invitrogen™ Life
Technologies, Carlsbad, USA) supplemented with 10% FCS (Biochrom, Berlin,
Germany) and penicillin-streptomycin (Sigma). HEK293T were transduced with
lentivirus produced using second generation lentiviral vectors (Plasmidfactory,
Bielefeld, Germany), as well as pLVX transfer vectors in HEK293T cells. H3.3-HA-
3XFLAG encoding pLVX vectors were obtained from BioCat GmbH for H3.3 wt,
H3.3-G34A, H3.3-G34L, H3.3-G34R, and H3.3-G34W. Constructs encoding for
H3.3-G34V, H3.3-K27M and H3.3-K36M were generated via site-directed muta-
genesis following the manufacturers protocol (Q5® Site-Directed Mutagenesis kit,
New England BioLabs, USA).
Immunohistochemistry. For immunohistochemical detection of the H3.3-G34W
mutation formalin fixed paraffin embedded GCT tissue sections were depar-
affinized in Roti-Histol (Carl Roth GmbH, Karlsruhe, Germany) and rehydrated in
isopropanol. Antigen retrieval was performed using Dako target retrieval solution
pH 6 (Dako, Hamburg, Germany) for 5 min at 121 °C in a pressure cooker. Sec-
tions were blocked for 30 min at room temperature using PBS supplemented with
5% bovine serum albumin (BSA). The primary rabbit anti-H3G34W antibody
(Active Motiv, Carlsbad, USA) was diluted 1:1000 in PBS/1% BSA and incubated
over night at 4 °C. The signal was amplified using the BrightVision +Poly-AP kit
(VWR, Darmstadt, Germany) according to the manufacturer´s instructions.
Samples were counterstained with hematoxylin (Carl Roth GmbH) and mounted
using Neo-Mount (Merck, Darmstadt, Germany). All used antibodies are listed in
Supplementary Table 1.
Lineage verification by flow-cytometric analysis. Stromal cells were harvested
by trypsination and transferred to 1,5 ml Eppendorf in PBS. Cells were washed with
PBS 2% FCS and centrifuged for 5 min at 250×g at 4 °C. The antibody staining
cocktail was prepared in PBS 2% FCS and cells were stained 20 min at 4 °C (all
antibodies are specified in the Supplementary Table 1; dilutions: anti-CD45, anti-
CD235, anti-CD105 1:50; anti-CD90 1:100). Afterwards cells were washed with
PBS 2% FCS to remove unbound antibodies and centrifuged at 250×g for 5 min. To
exclude dead cells during flow cytometric analysis, propidium iodide was added
prior to flow analysis. Data were acquired on a BD FACSAria Fusion (Beckton,
Dickinson and Company (BD)) and data were analyzed using FlowJo (BD). Prism
(GraphPad Software) was used to generate bar graphs. Hematopoietic/erythroid
cells were defined as CD45+CD235+, CD45−CD235− CD105+and CD45
−CD235− CD90+ cells were defined as mesenchymal cells. Freshly frozen iliac
crest bone marrow aspirates from healthy donors were used as healthy controls.
OPG expression quantification with ELISA. 5000 cells were seeded into a 96-well
plate and cultivated in 100 µl media for two days. Enzyme-linked immunosorbent
assay (ELISA) was performed with the Abcam human Osteoprotegerin ELISA Kit
following the manufacturer´s instructions.
Cell titer blue assay. Cells were cultivated in a 96-well plate. 100 µl fresh media
(DMEM/F12 no phenol red (Gibco, Invitrogen, Life Technologies, Paislay, UK)
supplemented with 10% FCS (Biochrom, Berlin, Germany) were added and sup-
plemented with 20 µl CTB reagent from Promega. After 2.5 h of cultivation at 37 °C
fluorescence was recorded at 560Ex/590Em.
siRNA knockdown. 120,000 cells were seeded into a 6-well plate. After 24 h,
medium was changed and transfection was performed using 1 µl Dharmafect1
(Horizon Discovery, Waterbeach, UK) reagent in combination with 2 µl of a 25 µM
siRNA SMARTpool of Dharmacon (Horizon Discovery, Waterbeach, UK) tar-
geting EBF2. Cells were harvested 48 h after transfection.
Detection of the H3F3A-G34W mutation by mutation-specific PCR. Genomic
DNA was isolated using the Quick DNA Miniprep kit (Zymo research, Freiburg,
Germany) according to the manufacturer’s protocol. PCR amplification was per-
formed using H3F3A wild-type and H3F3A-G34W specific primer, respectively.
The reaction consisted of 2 U Platinum Taq polymerase (Thermo Fisher Scientific,
Dreieich, Germany), 0.6 µl MgCl2 (50 mM), 0.4 µl dNTPs (10 mM each), 0.5 µl of
each primer (10 µM) and 100 ng genomic DNA as template in a total volume of
20 µl. Samples were incubated at 94 °C for 3 min followed by 34 cycles of dena-
turation at 94 °C for 15 s, annealing at 66 °C for 20 s and extension at 72 °C for 30 s
and a final extension step at 72 °C for 7 min. PCR products were separated on a
1.6% agarose gel, visualized by Midori Green (Biozym, Hessisch Oldendorf, Ger-
many) and imaged. All primers are listed in Supplementary Data 5.
Detection of the H3F3A-G34W mutation by Sanger sequencing. DNA was
extracted using the Qiamp Mini Kit (Qiagen, Hilden, Germany), according to the
manufacturer´s instructions. The PCR reaction to amplify the mutation spanning
H3F3A region consisted of 1U Hot Star Taq polymerase (Thermo Fisher Scientific,
Dreieich, Germany), 0.8 µl dNTPs (10 mM each, Fermentas, St. Leon-Rot, Ger-
many), 2 µl of each primer (10 µM, Sigma-Aldrich, Taufkirchen, Germany) and
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100 ng genomic DNA as template in a total volume of 40 µl. Samples were incu-
bated at 95 °C for 15 min followed by 10 cycles of denaturation at 94 °C for 45 s,
annealing at 61–56 °C for 30 s (touchdown −0.5 °C/cycle) and extension at 72 °C
for 60 s followed by 25 cycles of denaturation at 94 °C for 45 s, annealing at 56 °C
for 30 s and extension at 72 °C for 60 s and a final extension step at 72 °C for
10 min. Sequencing was performed by GATC Biotech AG, Konstanz, Germany. All
primers are listed in Supplementary Data 5.
Deep targeted resequencing using MiSeq. Deep resequencing of H3F3A
amplicons was performed according to52. DNA was extracted using the Qiamp
Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer´s instructions.
The PCR reaction to amplify the mutation spanning region of the H3F3A gene
consisted of 0.35U HotStart Q5 polymerase (NEB, Ipswich, USA), 0.6 µl dNTPs
(10 mM each, Fermentas, St. Leon-Rot, Germany), 0.3 µl of each primer (10 µM,
Sigma-Aldrich, Taufkirchen, Germany) and 25 ng genomic DNA as template in a
total volume of 25 µl. Samples were incubated at 98 °C for 1 min followed by 33
cycles of denaturation at 98 °C for 10 s, annealing at 61 °C for 30 s and extension at
72 °C for 20 s, and a final extension step at 72 °C for 2 min. Primer sequences are
listed in Supplementary Data 5. Primers included a sequence complementary to the
primers used for library preparation. Samples were separated on a 1.2% agarose gel
and DNA was visualized by Ethidium Bromide. Gel extraction was performed
using the Gel extraction Kit (Qiagen, Hilden, Germany). Libraries were prepared
using 12.5 µl NEB Next HF 2x PCR mix (New England Biolabs, USA) in combi-
nation with 0.75 µl of 10 µM IDT primers with Nextera handles and TruSeq
Unique-Dual Indices (IDT, USA), 0.3 µl 100× Sybr green and 11 µl of DNA (2 ng).
Amplification was performed for 6 cycles with the following progression: 98 °C 30
s, 98 °C 10 s, 62 °C 30 s, and 72 °C 15 s. Libraries were pooled and sequenced on a
single flow-cell lane in a or 300 bp paired-end MiSeq run (Illumina, San Diego, CA,
USA). The reads were demultiplexed using custom scripts, aligned to the GRCh37
assembly using bwa mem (v. 0.7.8)53 with default settings. Base frequencies were
read into R and analyzed using package deepSNV (v. 1.24.0)54.
Detection of genomic structural variations using M-FISH. Multiplex fluores-
cence in situ hybridization (M-FISH) was performed as described in55. Seven pools
of flow-sorted whole chromosome painting probes were amplified and directly
labeled by degenerative oligonucleotide primed (DOP)-PCR using CY-415-
aadUTP (Dyomics, Jena, Germany), Green-dUTP (Abbott, catalog number 02N32-
050), DY-547P1-aadUTP (Dyomics, Jena, Germany), DY-590-aadUTP (Dyomics,
Jena, Germany), and CY-647P1-aadUTP (Dyomics, Jena, Germany) conjugated
nucleotides or biotin-16-dUTP (Roche Diagnostics, Mannheim, Germany) and
digoxigenin-11-dUTP (Roche Diagnostics, Mannheim, Germany), respectively.
Prior hybridization, metaphase preparations of the H3.3 WT and H3.3 MUT cells
were digested with pepsin (0.5 mg/ml; Sigma-Aldrich, USA) in 0.2 N HCL (Carl
Roth GmbH, Karlsruhe, Germany) for 10 min at 37 °C, washed in PBS, post-fixed
in 1% formaldehyde, dehydrated with a degraded ethanol series and air dried.
Slides were denatured in 70% formamide/1× SSC/15% dextran sulfate for 2 min at
72 °C. Hybridization mixture consisting of 50% formamide, 2× SSC, Cot1-DNA,
and labeled DNA probes was denatured for 7 min at 75 °C, preannealed for 20 min
at 37 °C, and hybridized to the denatured metaphase preparations. After 48 h
incubation at 37 °C slides were washed at room temperature in 2× SSC, 3 × 5 min,
followed by 2 × 5min in 0.2% SSC/0.2% Tween-20 at 56 °C. For indirect labeled
probes, a immunofluorescence detection was carried out. Biotinylated probes were
visualized using three layers of antibodies: (1) streptavidin Alexa Fluor 750 con-
jugate (dilution 1:100 in 4× SSC/0.2% Tween-20), (2) biotinylated goat anti avidin
(dilution 1:200 in 4× SSC/0.2% Tween-20) (3) followed by a second streptavidin
Alexa Fluor 750 conjugate (dilution 1:100 in 4× SSC/0.2% Tween-20). Digoxigenin
labeled probe were visualized using rabbit anti digoxin (dilution 1:500 in 4 x SSC/
0.2% Tween-20) followed by goat anti rabbit IgG Cy5.5 (dilution 1:500 in 4× SSC/
0.2% Tween-20). All antibodies are summarized in Supplementary Table 1. Slides
were washed in 4× SSC/0.2% Tween-20, counterstained with 4.6-diamidino-2-
phenylindole (DAPI) and covered with antifade solution. Images of 20 metaphase
spreads of the H3.3 WT and H3.3 G34W cells were captured for each fluorochrome
using highly specific filter sets (Chroma technology, Brattleboro, VT), and pro-
cessed using the Leica MCK software (Leica Microsystems Imaging Solutions,
Cambridge, UK), respectively
Chromatin fractionation. Cell pellets were resuspended in lysis buffer (10 mM
HEPES pH 7.6, 10 mM KCl, 0.05% NP40) with protease inhibitors and incubated
on ice for 30 min. Samples were centrifuged at 16,000×g at 4 °C for 10 min and the
supernatant was taken as cytosolic fraction. Leftover pellet was further lysed with
low salt buffer (10 mM Tris HCl pH 7.5, 3 mM MgCl2) supplemented with 1%
Triton X-100 for 15 min on ice and centrifuged. Supernatant was taken as nuclear
proteins. Leftover pellet was resuspended in 0.2 M HCl, incubated on ice for 20 min
and centrifuged. The supernatant was neutralized with 1M Tris HCl buffer (pH8)
and used as the chromatin fraction.
Western blot. Proteins were separated using SDS polyacrylamide gel electro-
phoresis (SDS-PAGE) and analyzed by Western blotting using the antibodies listed
in the Supplementary Table 1. Antibody dilutions: anti-β-actin 1:5000, anti-H3.3
1:250, anti-H3.3-G34W 1:500, anti-H3K36me2 1:500, anti-HK36me3 1:500, anti-
H4 1:500, anti-DAXX 1:1000, anti-α-tubulin 1:2000, anti-FLAG 1:1000. Chemi-
luminescence signals were imaged using Amersham Imager 680 (GE, Boston,
USA). For the separation of endogenous histone H3 proteins and ectopically-
expressed H3.3-HA-3XFLAG in HEK293T, we used 8–16% Mini-PROTEAN®
TGX gels (Bio-Rad Laboratories).
Differentiation and alkaline phosphatase staining. 50.000 cells were seeded in
24-well plates. When confluent medium was changed to osteogenic differentiation
medium: DMEM high Glucose mit L-Glutamin supplemented with 10%FCS,
0.1 µM Dexamethason, 0.17 mM Ascorbinsäure-2-phosphat, and 10 mM ß-
Glycerophosphat. Alkaline phosphatase activity was analyzed using BCIP/NBT
Alkaline Phosphatase Substrate Kit (Vector Laboratories, Burlingame, CA, USA)
after 1 min of 4% PFA fixation.
Quantification of ALP activity. 50,000 cells were seeded in 24-well plates. When
confluent media was changed to differentiation media (compare Differentiation
and alkaline phosphatase staining) and the first measurement was performed. After
CTB as described above, wells were PBS washed and fixated for 60 s with 4% PFA
in PBS. After PBS washing 500 µl Alkaline Phosphatase Yellow (pNpp) Liquid
Substrate (System for ELISA, Sigma-Aldrich, USA) was added and incubated at
37 °C for 8 min. Absorbance was measured at 405 nm.
Whole-genome sequencing and analysis. Read pairs were mapped to the human
reference genome (build 37, version hs37d5), using bwa mem (v. 0.7.8)53 with
minimum base quality threshold set to zero [-T 0] and remaining settings left at
default values, followed by coordinate-sorting with bamsort (with compression
option set to fast REF1) and marking duplicate read pairs with bammarkduplicates
(with compression option set to best56); both are part of biobambam package
(v.0.0.148)57. Somatic SNVs were identified with the DKFZ SNV-calling work-
flow58. Somatic SNVs and indels in matched tumor normal pairs were identified
using the DKFZ core variant calling workflows of the ICGC Pan-cancer Analysis of
Whole Genomes (PCAWG) project (https://dockstore.org/containers/quay.io/
pancancer/pcawg-dkfz-workflow). Tumor and matched control samples were
analyzed by Platypus (v. 1.0)59 to identify indel events. SNVs and indels from all
samples were annotated using ANNOVAR (v. 2017Jul16)56 according to GEN-
CODE gene annotation (v. 19) and overlapped with variants from dbSNP10 (build
141) and the 1000 Genomes Project database. Genomic structural rearrangements
were detected using SOPHIA (v.34.0) (https://bitbucket.org/utoprak/sophia/src) as
described in ref. 60. Briefly, SOPHIA uses supplementary alignments as produced
by bwa mem as indicators of a possible underlying SV. SV candidates are filtered by
comparing them to a background control set of sequencing data obtained using
normal blood samples from a background population database of 3261 patients
from published TCGA and ICGC studies and both published and unpublished
DKFZ studies, sequenced using Illumina HiSeq 2000 (100 bp), 2500 (100 bp), and
HiSeq X (151 bp) platforms and aligned uniformly using the same workflow
as in this study. An SV candidate is discarded if (i) it has more than 85% of
read support from low quality reads; (ii) the second breakpoint of the SV was
unmappable in the sample and the first breakpoint was detected in 10 or more
background control samples; (iii) an SV with two identified breakpoints had one
breakpoint present in at least 98 control samples (3% of the control samples);
or (iv) both breakpoints have less than 5% read support. Statistics over SVs for
9 samples with matched control and integrated variant analysis over all samples
were based on SOPHIA calls. Allele-specific copy-number aberrations were
detected using ACEseq (v. 1.0)61. SVs called by SOPHIA were incorporated to
improve genome segmentation.
Whole-genome sequencing data of bone cancer and glioblastoma. WGS data
of 73 bone cancer patients (BOCA cohort) were obtained via the Pan-cancer
Analysis of Whole Genomes Project62. Pediatric glioblastoma data (PGBM cohort)
were obtained from PedBrain Tumor Project of the International Cancer Genome
Consortium20. The processing and variant calling (SNVs, SVs, CNVs) was per-
formed consistently with the GCTB data as described above. To balance sample
sizes for the analysis of recurrent genetic events, in addition to analyzing the
complete BOCA cohort (Supplementary Fig. 1i), we draw several random 10-
patient subsets, one of which is shown in Fig. 1d. From the PGBM cohort only
10 samples with H3.3-G34R mutation were selected for the analysis. Patient
identifiers of all WGS samples are given in Supplementary Data 1.
ATAC-sequencing and analysis. Libraries for ATAC-sequencing were prepared
in accordance with the original protocol with minor modifications63. 50,000 cells
were lysed by 1% NP40 and PBS washed. After centrifugation at 1200×g for 10 min,
tagmentation at 55 °C for 8 min in a reaction mix with 2.5 µl of TDE1 (Nextera
Illumina DNAKit), 25 µl Tagmentation buffer (Nextera Illumina DNA Kit) and
22 µl water took place. Reaction was stopped by adding 10 µl Guanidium (5M) and
samples were purified using 72 µl Ampure Beads. Libraries were generated using
NEBNext High Fidelity PCR Mix and sequenced on the Illumina HiSeq 2000
platform. Sequencing reads were adapter-trimmed using cutadapt (v. 1.10)64.
Genomic alignments were performed against the human reference genome (hg19,
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NCBI build 37.1) using Bowtie2 (v. 2.3.0)65. The non-default parameters -q 20 -s
were used. PCR duplicates were removed by Picard MarkDuplicates (v. 1.125).
Signal tracks were generated using deepTools (v. 2.3.3)66. A compatible CWL-based
ATAC-seq data processing workflow is available at https://github.com/
CompEpigen/ATACseq_workflows. Peaks were called using Macs2 (v. 2.1.1.)67
with the parameters –nomodel –shift -50 –extsize 100 –qvalue 0.01. All peaks were
merged to create a common bed file with read counts before differential analysis
using edgeR (v. 0.3.16)68. Gene annotations were made using ChIPpeakAnno (v.
3.18.0)69. Transcription binding motif analysis was performed using HOMER (v.
4.9)70. Motifs with a P-value <0.01 and a ratio of motif to background above 1.1
were defined as significantly enriched.
ChIP-sequencing and analysis. We used the ChIP-mentation protocol71 to map
the genomic distribution of WT and G34W H3.3, total H3, as well as 6 histone
modifications (H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, and
H3K36me3) in a subset of samples (see details in Supplementary Data 1). To
confirm the specificity of the H3.3 and H3.3 G34W antibody used for ChIP-Seq
analysis, we performed a validation experiment with a Histone code peptide array
(JPT, Berlin, Germany) containing short peptides that densely cover most of the
known histones and their modifications. We did not observe any significant
binding of the G34W-speicifc antibody to H3.3 peptides and a highly specific
binding of the H3.3 antibody. Cells of a confluent T175 flask were harvested by
TrypLE incubation After centrifugation for 5 min at 1000 xg, cells were washed in
PBS, distributed into 750.000 cell aliquots and pelleted again. The cell pellet fixed in
8 ml 1% FA in PBS at room temperature for 10 min. Crosslinking was stopped by
the addition of 400 μl 2.5 M glycine. Cells were pelleted, resuspended in 1 ml ice
cold PBS supplemented with 1x protease inhibitor and again pelleted at 3000×g for
3 min at 4 °C. The supernatant was taken off and the pellet was resuspended in 130
μl FL buffer supplemented with 2× protease inhibitor and transferred to an AFA
Covaris 130 μl tube. For nuclei isolation, cells were sheared with a duty factor of
2.5, 200 burst and 40 watts for 3–10 min using the Covaris M220. The nuclei were
spinned down for 3 min at 4 °C. The nuclei pellet was resuspended in 130 μl
shearing buffer and shearing with a duty factor of 5, 75 watt and 200 burst was
performed for 10–12 min with the Covaris M220. 100-200 ng sheared DNA were
filled up to 200 μl with dilution buffer and mixed with 1 µg antibody and rotated
over night at 4 °C. The storage solution of 20 μl Protein A beads per IP was taken
off using a magnet and the beads were washed with 500 μl PBS supplemented with
0.1% BSA. To block the beads, they were resuspended in 150 μl PBS with 0.1% BSA
and also rotated over night at 4 °C. The next day, the PBS was taken off from the
beads with the help of a magnet and beads were taken up in 20 μl dilution buffer.
The bead-dilution buffer mixture was added to the sheared DNA-antibody mixture
and rotated for 2 h at 4 °C. The supernatant of the mixture was taken off with the
help of a magnet and the bead-bound chromatin antibody conjugate was washed
twice with 500 μl WB1, once with WB2 and once with WB3. Two more washing
steps with 10 mM Tris HCl ph8 took place. Beads were then resuspended in 30 μl
tagmentation mix (15 μl tagmentation buffer, 14 μl water, 1 μl TDE1 (Nextera
Illumina DNA Kit)) and incubated for exactly 10 min at 37 °C. The tagmentation
mix was removed and beads were washed twice with 500 μl Tn5 buffer. DNA
elution took place by incubation of the beads in 100 μl ChIP-mentation elution
buffer supplemented with 2 μl proteinase K for 2 h at 55 °C and 8 h at 65 °C. The
supernatant containing the DNA was mixed with 200 μl AMpure beads for pur-
ification. For elution, beads were mixed with 26 μl water and incubated for 3 min at
room temperature. Beads were collected with a magnet and the supernatant was
collected as it contained the DNA with added adapters. Barcode amplification was
performed with 24 μl sample. 0.8 μl universal Tn5 fwd primer and 0.8 μl barcode
primer, both complementary to the transposase added adapters, as well as 25 μl
NEB Next High Fidelity 2× mix and 0.3 μl 100× Sybr green. Samples were incu-
bated at 72 °C for 5 min for gap repair followed by 30 s incubation at 98 °C. Cycles
of denaturation at 98 °C for 10 s, annealing for 30 s at 63 °C and extension at 72 °C
for 30 s were repeated until the amplification curve almost reached saturation but
for maximum 16 cycles. 70 μl AMpure beads were added to the PCR mixture for
purification. For elution, beads were mixed with 20 μl elution buffer and incubated
for 3 min at room temperature. Beads were collected with a magnet and the
supernatant was collected as it contained the library. The detailed composition of
all buffers is described in the original publication. Up to 4 libraries were equi-
molarly pooled and sequenced in a 125 bp paired end run on a HiSeq machine.
Sequence reads were preprocessed using cutadapt (v. 1.10)64 and aligned with
Bowtie2 (v. 2.3.0)65 with the default command line options. A compatible CWL-
based ChIP-seq data processing workflow is available at https://github.com/
CompEpigen/ChIPseq_workflows. We used deepTools (v. 2.3.3)66 with non-default
options –binSize 10 –extendReads 400 –normalizeTo1x 2451960000
–ignoreForNormalization chrX to quantify genomic coverage in fixed-size window
intervals for meta-plots and heatmaps.
Calling of H3.3-G34W enriched regions. We used the Poisson test-based
binarization module of the ChromHMM software (v. 1.18)72 to generate 200 bp
windows with statistically significant enrichment of the wild-type H3.3 or H3.3-
G34W signal over a simulated background. Adjacent windows were merged to
generate primary enrichment regions. The regions were filtered against a union of
the ENCODE ChIP-seq blacklists.
Whole-genome bisulfite sequencing and analysis. WGBS Libraries were pre-
pared using the TruSeq DNA PCR-Free LT Library Preparation Kits with partially
modified steps in fragmentation and bead clean up/size selection. Briefly, 2 µg
genomic DNA (diluted in nuclease-free water) was fragmented to 150–200 bp
using a Covaris ultrasonicator (Covaris, Inc.) and quality checked using Agilent
TapeStation (Agilent Technologies). The fragmented DNA sample was diluted with
water and split into two aliquots of ~1 µg in 50 µl, end-repaired and purified using
1.6X sample purification beads. Adenylation of 3′ ends and ligation of TruSeq LT
adapters were performed as described in manufactures protocol. Then, adapter-
ligated fragment libraries were treated with bisulfite using the EpiTect Bisulfite Kit
(Qiagen) following the instructions in the Illumina WGBS for Methylation Ana-
lysis Guide. After bisulfite conversion the fragment libraries were enriched with 8
cycles of PCR using KAPA HiFi Uracil+ DNA Polymerase with customized primer
(Supplementary Data 5) and an annealing temperature of 69 °C according to the
settings for PE libraries in the technical Data Sheet (KAPA HiFi HotStart Uracil+
Ready Mix, KR0413-version 1.12, peqlab). Amplified libraries were purified with
1× Agencourt AMPure XP beads (Beckman Coulter Inc.) and quantified using
Qubit fluorometer (Life Technologies-Invitrogen). Then both aliquots of one
sample were pooled, validated using Agilent TapeStation and again quantified
using Qubit fluorometer. The final libraries were pooled and clustered on the cBot
(Illumina) according to the manufacturer’s instructions with a final concentration
of 250 pM, spiked with 5% PhiX control v3. Paired-end 150 bp sequencing on
HiSeq X was performed using standard Illumina protocols. Basic statistics about
the sequencing results is given in Supplementary Data 1. Raw reads were processed
using Trimmomatic (v. 0.36)73 and aligned against reference sequence of the
Genome Research Consortium (v. 37) using bwameth (https://github.com/brentp/
bwa-meth) wrapping bwa mem (v. 0.7.8)53 with default parameters, except for
invoking-T 0. After alignment duplicates were marked by applying Picard Mark-
Duplicates (v. 1.125). Methylation calling was performed with MethylDackel (v.
0.3.0). A compatible CWL-based data processing workflow for bisulfite sequencing
is available at https://github.com/CompEpigen/WGBS_workflows (BWA_meth_-
start_with_trimmed.cwl). Subsequently and prior to DMR calling, BSmooth was
used (v. 1.4.0) with default parameters to smooth the processed methylation
profiles in all samples74. We then used we DSS (v. 2.27.0)75 to call DMRs for
pairwise comparison between H3.3 WT and H3.3 MUT cells. Regions with at least
3 CpGs, a minimum length of 50 bp and a Benjamin-Hochberg corrected P value
<0.05 were selected. All DMRs were filtered requiring a minimal mean
methylation-value difference of 0.1.
HumanMethylation450 and HumanMethylationEPIC analysis. Methylation
analysis using HumanMethylation450 arrays was performed by the Genomics and
Proteomics Core Facility according to the manufacturer’s instructions. Profiling of
isogenic HeLa cell lines with HumanMethylationEPIC arrays was conducted at
Korean Cancer Center according to the manufacturer’s instructions. Unnormalized
signals (IDAT files) were loaded into R using RnBeads software (v. 2.2.0)76 and
subjected to preprocessing with default option settings. 10,000 sites most variable
across all samples were used for both, Principal Component Analysis and clus-
tering analysis, visualized as a heatmap.
RNA-sequencing and analysis. Poly-A RNA sequencing of GCTB samples was
performed according to the standard protocol77. Total RNA was prepared for each
cell line by using the RNeasy Mini kit (Qiagen, Hilden, Germany) and library
preparation was done using TruSeq Stranded mRNA Kit (Illumina), according the
manufacturer’s instruction. Paired-end 125 bp sequencing runs were performed on
Illumina Hiseq2000 v4 machines. Raw sequence reads were preprocessed using
cutadapt (v. 1.10)64 to remove sequencing primers and adapters. Reads were
aligned to the GRCh37 human reference genome with HISAT2 (v. 2.0.4)78 with
additional non-default parameters –max-intronlen 20000 –no-unal –dta. Tran-
scripts were assembled and quantified with StringTie (v. 1.3.3)79 with the GRCh37
transcript database. The RNA-seq processing workflow is available from https://
github.com/CompEpigen/RNASeq_GCTB. Differential expression analysis was
performed using DeSeq2 (v. 1.18.1)80. Genes were called differentially expressed at
FDR 0.05 and the absolute log-fold difference of greater or equal to one.
RNA-Seq of the differentiation samples. RNA-seq of the MSC differentiation
samples was performed according to the following protocol. 50,000 cells were
seeded in 6-well plates in maintenance medium: MesenPRO-RS™ (Thermo Fisher
Scientific, Massachusetts, USA). After 3 days, medium was replaced with osteo-
genic differentiation medium: DMEM high glucose supplemented with 10% FBS,
1× non-essential amino acids (NEAA), 2 mM L-glutamine, 0.28 mM ascorbic acid,
10 mM β glycerophosphate, and 10 nM dexamethasone (Sigma-Aldrich, USA). At
each time-point: 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 125, 168, 336, and 504 h
during osteogenesis, total RNA was isolated using TRIzol (Invitrogen™ Life
Technologies, Carlsbad, USA) with the Direct-zol RNA kit (ZymoResearch, USA)
according to the manufacturer’s instruction. RNA-seq library preparation was
carried out using the NEBNext Poly(A) mRNA Magnetic Isolation Module and
NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England
Biolabs, USA) according to the manufacturer’s instruction. The quantity and
quality of the cDNA library were assessed using the Agilent 2200 tapestation
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(Agilent Technologies, Santa Clara, USA). Paired-end sequencing of the pooled
library was carried out using the Illumina NextSeq 500 v2 kit (Illumina, San Diego,
USA) according to the manufacturer’s instruction.
qRT-PCR expression analysis. Total RNA was extracted using the RNeasy Mini
kit (Qiagen, Hilden, Germany). cDNA was synthesized using random hexamers
(Qiagen, Hilden, Germany), and Superscript III Reverse Transcriptase (Invitrogen,
Life Technologies, Paislay, UK) according to the manufacturer’s instructions. qPCR
mixture consisted of 3.5 µl Light Cycler 480 Probe master (Roche Diagnostics,
Mannheim, Germany) 1 µl 10 µM Primer mix (Sigma-Aldrich, Taufkirchen, Ger-
many) and 0.05 µl UPL probe (Roche Diagnostics, Mannheim, Germany). 2.5 µl of
a 1:10 dilution of cDNA served as template. Expression analysis was performed on
the LightCycler 480-2 (Roche) system with the following progression: 10 min 95 °C
and 45 cycles of 10 s 95 °C, 20 s 55 °C, 1 s 72 °C. Alternative to the UPL system,
Sybr green qPCR was performed in a total volume of 10 µl including 5 µl Prima
Quant Mix (Steinbrenner, Wiesenbach, Germany), 0.6 µl Primermix (10 µM each,
Sigma-Aldrich) and 2 µl of 1:10 dilution of the template cDNA. Samples were
incubated at 95 °C for 15 min and 15 s at 95 °C, 30 s at 55 °C, and 10 s at 72 °C for
45 cycles. Target gene expression was normalized to the housekeeping gene
GAPDH using the ΔCT method (relative expression is equal to 2-ΔCT). All used
primers are listed in Supplementary Data 5.
Targeted DNA methylation analysis using MassARRAY. Bisulfite treatment
was performed with the EZ DNA Methylation Kit from Zymo Research following
the manufacturer’s protocol. PCR was performed with primers listed in Supple-
mentary Data 5 using the Qiagen HotStar Taq (Qiagen, Hilden, Germany). The
Shrimp alkaline phosphatase step and in vitro transcription were performed with
the EpiTYPER Reagent Set from Agena Bioscience following the manufacturer’s
protocol. Analyses were performed on the Sequenom Platform (Agena Bioscience,
San Diego, USA).
Gene and genomic feature annotations. Unless specified otherwise, Ensembl
transcript and gene annotations were used for the GRCh37 assembly (build 87).
List of bivalent genes in H3.3 WT was compiled by overlapping the consensus H3.3
WT peaks of H3K27me3 and H3K4me3 within 2 kb from a RefSeq TSS. A con-
sensus list of bivalent genes in human ESCs was obtained from ref. 81. A list of
PRC2 target genes was found in ref. 82. A comprehensive list of imprinted genes
was obtained from ref. 83. Replication timing domains for the annotation of LMDs
originates from Repli-Seq data of ref. 84, processed and publicly deposited by
RepliScan package85. MSC-specific chromatin states were taken from the 15-state
ChromHMM model72 for bone-marrow derived MSCs generated by the Roadmap
Epigenomics consortium21 (sample E026).
Identification of large-scale methylation domains. DNA methylation data was
summarized in 20 kb tiling windows to eliminate the small-scale variability (e.g.,
related to CpG islands). The changepoints were then called using R package
changepoint (v. 2.2.2). DNA methylation data was summarized in the obtained
segments and the latter were clustered using standard hierarchical clustering
resulting in 6 stable clusters. After clustering adjacent segments that belonged to
the same cluster were merged. Two smallest clusters were removed since one
contained less then 10 segments and the other one exclusively Y-chromosome
segments. R code for LMD identification is available from https://github.com/
lutsik/CP-LMDs. For gene density estimation UCSC hg19 human gene annotation
(R package xDb.Hsapiens.UCSC.hg19.knownGene) were used and for each LMD
segment the number of overlapping genes was divided by its length in
megabases (Mb).
Genomic overlap enrichment analysis. We tested the significance of overlap of
differential ATAC-seq peaks, H3.3 G34W incorporation regions and other regions
of interest with publicly available genomic annotations using LOLA (v. 1.8.0)86. In
the case of ATAC peaks a union of all called peaks in H3.3 WT and H3.3 MUT was
used as background to test enrichments at H3.3 G34W gained and lost peaks
relative to each other. For H3.3 WT and G34W enrichment regions the back-
ground set consisted of regions called for wild-type H3.3 in H3.3 WT and H3.3
MUT groups, as well as the H3.3-G34W regions. We used the LOLA core database
for most of the analyses. Enrichment of repeat elements was based on a custom
LOLA database created using the UCSC Repeat Masker track (http://www.
repeatmasker.org).
Gene set overrepresentation and enrichment analysis. We used gene sets from
the Molecular Signatures Database v. 6.2 (MSigDB)87 to test for the over-
representation of DEGs or genes associated with differential ATAC peaks, and the
gene set enrichment analysis (GSEA) of DEGs. Overrepresentation analysis was
performed with the help of R package GeneOverlap (v. 1.14.0). GSEA was per-
formed with fgsea package (v. 1.4.1)88 using 10,000 permutations.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All raw patient-derived sequencing data from WGS, WGBS, ATAC-seq, ChIP-seq, RNA-
seq and deep targeted resequencing have been deposited in the European Genome-
Phenome Archive (EGA) under restricted access with the accession code:
EGAS00001003730. Processed sequencing data and microarray data have been deposited in
ArrayExpress with the accession codes: E-MTAB-7184 (ChIP-Seq), E-MTAB-9512 (ATAC-
Seq), E-MTAB-9513 (WGBS), E-MTAB-9515 (RNA-Seq). RNA-Seq data of the MSC
osteogenic differentiation experiment are deposited at the Gene Expression Omnibus
(GEO) with the accession code: GSE129036. We furthermore used gene sets from the
Molecular Signatures Database v. 6.2 (MSigDB): https://www.gsea-msigdb.org/gsea/msigdb/
download_file.jsp?filePath=/msigdb/release/6.2/msigdb_v6.2_files_to_
download_locally.zip, ChromHMM states of human bone-marrow by ENCODE project
(sample E026): https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmenta
tions/ChmmModels/coreMarks/jointModel/final/E026_15_coreMarks_segments.bed,
Replication timing segments by Repliscan project (Hansen et al., 2010): https://de.cyverse.
org/anon-files/iplant/home/gzynda/public/hansen2010_replicate/repliscan_50kb.gff3,
Consensus list of ESC-specific bivalent genes81: http://www.oncotarget.com/index.php?
journal=oncotarget&page=article&op=downloadSuppFile&path%5B%5D=
13746&path%5B%5D=21048 LOLA Core database of functionally annotated genomic
regions: http://big.databio.org/regiondb/LOLACore_180423.tgz. Database of common
variant calls from the 1000 Genomes Project: http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
release/20130502/. GRCh37 transcript database ftp://ftp.ncbi.nlm.nih.gov/refseq/H_sapiens/
annotation/GRCh37_latest/refseq_identifiers/GRCh37_latest_genomic.gff.gz Repeat
masker database: http://www.repeatmasker.org Source data are provided with this paper.
Code availability
All presented results were obtained with the use of published and publicly available
software tools introduced in the Methods section. Essential custom code is available from
dedicated code repositories specified in the descriptions of respective computational
methods above. DKFZ/PCAWG WGS analysis workflow is available as a Docker
container from: https://dockstore.org/containers/quay.io/pancancer/pcawg-dkfz-
workflow. Compatible CWL workflows for WGBS, ATAC-Seq and ChIP-Seq data
processling are publicly available on Github/CompEpigen: https://github.com/
CompEpigen/WGBS_workflows (BWA_meth_start_with_trimmed.cwl) https://github.
com/CompEpigen/ATACseq_workflows https://github.com/CompEpigen/
ChIPseq_workflows. A snakemake-based processing workflow for RNA-seq data is
available at: https://github.com/CompEpigen/RNASeq_GCTB. Custom code for LMD
calling using changepoint algorithms is available at: https://github.com/lutsik/CP-LMDs.
Other custom code is available at https://github/lutsik/GCTB_Epigenome.
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